Pazopanib does not bring remarkable improvement in patients with angiosarcoma

Abstract

Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that has been reported to extend progression-free survival in cases of metastatic soft-tissue sarcoma. However, the efficacy of pazopanib for cutaneous angiosarcoma has not been confirmed. We report eight cases of angiosarcoma treated with pazopanib, and review the efficacy and safety of pazopanib therapy. We retrospectively investigated the clinical information, including age, sex, body surface area, location, performance status, lung or pleural metastasis, preceding treatment, oral dose of pazopanib, response rate, progression-free survival and adverse effects. Five of the eight patients needed to stop the pazopanib treatment due to severe adverse effects, including thrombocytopenia, anemia, drug-associated pancreatitis, acute fulminant hepatitis and general fatigue. Progression-free survival ranged 0.5-3.5 months (mean ± standard deviation, 1.81 ± 1.03). Overall survival ranged 3-26 months (14.13 ± 9.47). Six of the eight cases showed progressive disease, and two of the eight cases showed stable disease. To assess overall survival in angiosarcoma treated with pazopanib, we compared the pazopanib-treated group (n = 8) with the non-pazopanib-treated control group (n = 10). There was no significant difference between two groups (P = 0.19, log-rank test). In conclusion, our case series suggests that pazopanib does not bring remarkable improvement in patients with angiosarcoma.

Prognostic value of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography in patients with cutaneous angiosarcoma: A retrospective study of 18 cases

“…However, Kitamura et al . have reported that pazopanib does not bring remarkable improvement in patients with CAS . Thus, the benefits of novel agents for CAS are still controversial.…”

“…5 However, Kitamura et al have reported that pazopanib does not bring remarkable improvement in patients with CAS. 15 Thus, the benefits of novel agents for CAS are still controversial. An early assessment of prognosis using SUV max at the initial visit may be helpful for the selection of therapies among conventional taxane chemotherapy and newly developed therapies.…”

Three patients with advanced cutaneous angiosarcoma treated with eribulin: investigation of serum soluble CD163 and chemokine (C-X-C motif) ligand 10 as possible biomarkers predicting the biological behaviour of angiosarcoma

“…In another report, Kitamura et al . described eight individuals with CAS treated with pazopanib, suggesting that pazopanib does not achieve marked improvements in the overall survival of patients with CAS . Definitive rules for the selection of second‐line agents are thus lacking.…”

Evaluation of pazopanib cytotoxicity to normal vascular endothelial cells in vitro: A comment on Goto et al.

“…Previously, we reported eight cases of AS treated with pazopanib, and the average PFS of these eight cases was only 1.81 months. 5 Thus, we think that the clinical efficacy of pazopanib as a treatment for AS is limited.…”